Genomics technologies such as next-generation sequencing (NGS) and microarrays are accelerating neurogenomics research by revealing the mechanisms behind complex neurological diseases such as Alzheimer’s disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and psychiatric disorders.
The interplay between heritable and nonheritable mutations, epigenetics, and other factors requires NGS-level analyses to increase our understanding. Arrays facilitate large-scale studies of genetic variants associated with neurological diseases. Illumina offers the NGS and microarray tools needed to make genomic neuroscience research possible.
TruSeq Neurodegeneration Panel: This NGS panel covers 118 risk genes associated with common neurodegenerative diseases, including Alzheimer’s disease, Parkinson's disease, ALS, and others.
Infinium PsychArray BeadChip: This array allows researchers to evaluate genetic variants associated with common psychiatric disorders.
Kailos TargetRich PGxComplete: This enrichment-based targeted sequencing research panel covers 43 genes associated with responses to ~100 medications.
Kailos Blue Analytics: These solutions provide sequencing quality assessment, alignment, and variant calling in output formats suitable for use with a variety of reporting solutions.
Learn how integrating whole-genome or whole-exome sequencing data with transcriptome information (from RNA-Seq) and epigenetic information (from methylation arrays) in stem cells and tissue types of interest can help identify genes and pathways that have a role in neurological diseases.View Webinar
Neuroscience researchers use NGS to identify variants for a microarray designed for ADHD, autism, and schizophrenia studies.Read Interview
Experts discuss the genetics of dementia in this podcast episode, hosted by the UK Dementia Research Institute and Illumina.Listen Now
Dr. Franco Taroni uses targeted sequencing to uncover novel genomic variants associated with metabolic and neurological disorders.Read Interview
Researchers in the neurogenomics community contributed content for the Neuro Consortium Array, a high-density array featuring over 180,000 markers associated with common neurodegenerative diseases. The array offers a high-throughput genotyping solution for fine mapping and replication of disease-associated variants.Learn More
Through this consortium, scientists selected content for the TruSeq Neurodegeneration Panel based on recent scientific findings. The TruSeq Neurodegeneration Panel offers a high-throughput approach to identifying and validating variants associated with risk for multiple neurodegenerative diseases.Learn More
Dr. Jacob Michaelson, Associate Professor of Psychiatry at the University of Iowa, discusses how he uses genomic and computational techniques to study autism and other psychiatric disorders.Listen Now
Dr. Michael R. Wilson, Assistant Professor of Neurology at the University of California San Francisco, discusses how genomics can shed light on causes of brain inflammation.Listen Now
Dr. Ted Abel, Director of the Iowa Neuroscience Institute, discusses transcriptional and epigenetic changes associated with long-term memory.Read Interview
Genomic technologies are introducing new avenues for understanding complex disease etiology on a molecular level.Learn More
Whole-genome sequencing and other genomic technologies can help scientists identify genetic variants linked to rare disorders.Learn More